Lieber Institute for Brain Development

Blackbird Labs, a Next-Generation Life Sciences Accelerator, Launches with $100 Million and Foundational Collaboration with Johns Hopkins University

Retrieved on: 
Mardi, novembre 7, 2023
UMB, Colitis, DSM-IV codes, History of the University of Maryland, College Park, Innovation, Crohn's disease, Johns Hopkins University, RNA, Johns Hopkins, Biotechnology, Laboratory, University of Maryland, College Park, Research, Inflammation, RA, Lieber Institute for Brain Development, Drug development, Senior, Scripps Research, Clinical trial, Economic development, Ecosystem, Schizophrenia, Messenger, University, Senior advisor, Cancer, Entrepreneurship, Economy, Patient, Pharmaceutical industry, Management

BALTIMORE, Nov. 7, 2023 /PRNewswire/ -- Blackbird Laboratories, Inc. ("Blackbird Labs"), a next-generation life sciences accelerator, today announced that it has launched with a $100 million founding grant from The Stephen and Renee Bisciotti Foundation and research collaborations with Johns Hopkins University, the University of Maryland, Baltimore, and the Lieber Institute for Brain Development. Blackbird Labs' mission is to accelerate the development and commercialization of novel medicines and cutting-edge technologies to enhance the well-being of patients facing unmet medical needs.   

Key Points: 
  • Blackbird Labs provides capital, program management, and strategic scientific and business input from its newly recruited team of life sciences professionals, seeking to bridge the gap between pioneering academic science and industry.
  • Blackbird Labs is led by Matt Tremblay, Ph.D., the CEO and a founding member of the board of directors since Blackbird Labs' creation in January 2023.
  • Blackbird Labs launches with a world-class group of advisors spanning the global life sciences venture investment community and business leaders.
  • "Blackbird Labs is an exciting new element of our innovation ecosystem, a unique resource for funding and expertise to help bring Johns Hopkins technologies to market.

BullFrog AI Announces Three-Year Global Strategic Partnership with the Lieber Institute for Brain Development

Retrieved on: 
Mercredi, septembre 13, 2023
Psychiatry, DSM-IV codes, DNA, LIBD, Partnership, Drug development, Clinical trial, Intelligence, Research, Brain, Biomarker, Lieber Institute for Brain Development, Collection, Myenteric plexus, Machine learning, Medicine, Artificial intelligence, DNA methylation, Gene, Bullfrog, Medical device

GAITHERSBURG, Md., Sept. 13, 2023 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ:BFRG; BFRGW) ("BullFrog AI" or the "Company"), a technology-enabled drug development company using artificial intelligence (AI) and machine learning to enable the successful development of pharmaceuticals and biologics, today announced a three-year global strategic partnership with the Lieber Institute for Brain Development (LIBD), a non-profit research institute that maintains the world's largest repository of postmortem brains for the study of neuropsychiatric disorders.

Key Points: 
  • GAITHERSBURG, Md., Sept. 13, 2023 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ:BFRG; BFRGW) ("BullFrog AI" or the "Company"), a technology-enabled drug development company using artificial intelligence (AI) and machine learning to enable the successful development of pharmaceuticals and biologics, today announced a three-year global strategic partnership with the Lieber Institute for Brain Development (LIBD), a non-profit research institute that maintains the world's largest repository of postmortem brains for the study of neuropsychiatric disorders.
  • Under the terms of the agreement, BullFrog AI will leverage its bfLEAP™ platform to mine LIBD's comprehensive brain data, including transcriptomic, genomic, DNA methylation, cell-line, clinical, and imaging data.
  • Throughout the collaboration, BullFrog AI will receive access to LIBD’s collection of brain data for further analyses and additional research projects.
  • The agreement specifies sharing of revenue between BullFrog AI and LIBD from products or services generated from the partnership.

Maryland Stem Cell Research Commission Announces Over $14 Million in Awards to Accelerate Cures

Retrieved on: 
Mardi, mai 9, 2023
Linda, Heart, Kennedy Krieger Institute, State, RFA Argus (A135), University, Face, Lieber Institute for Brain Development, Commission, Women of Discovery Awards, Eye, University of Maryland, College Park, Cancer, DRS, Research, College Park, Sympathetic nervous system, History of the University of Maryland, College Park, Johns Hopkins University, Patient, Geneva, Blood, Outline of health sciences, Hugo, 427th Maryland General Assembly, Sumathi Best Commercial Award, Pharmaceutical industry, Dentistry, Medical device

COLUMBIA, Md., May 9, 2023 /PRNewswire/ -- The Maryland Stem Cell Research (MSCRF) Commission is pleased to announce  over $14.1 million in grant awards to promote innovative research that will strengthen and advance stem cell treatments and technologies in Maryland. This is the largest amount awarded to Maryland-based institutions and companies since 2010 and was made possible as a result of increased funding from the State. This is also the first time that the Commission awarded funding to Maryland-based companies under MSCRF's new Manufacturing Assistance Program, established to boost cell therapy manufacturing capabilities in the State. 

Key Points: 
  • Commission also Issues Request for Applications for Four Funding Programs for July 13, 2023, Deadline
    COLUMBIA, Md., May 9, 2023 /PRNewswire/ -- The Maryland Stem Cell Research ( MSCRF ) Commission is pleased to announce  over $14.1 million in grant awards to promote innovative research that will strengthen and advance stem cell treatments and technologies in Maryland.
  • "We remain committed to supporting the researchers and companies in Maryland to advance stem cell research and ultimately improve the lives of patients suffering from a wide range of diseases and conditions," said Diane Hoffmann, chair of the Maryland Stem Cell Research Commission.
  • The Commission has also issued RFAs for its first-round of 2024 funding in hopes of continuing to accelerating cutting-edge research and cures through the various programs of the Maryland Stem Cell Research Fund (MSCRF) .
  • Manufacturing Assistance: These awards provide company support for manufacturing stem cell therapy products in Maryland.

VISIMO and West Point Advancing Artificial Intelligence for Judge Advocates

Retrieved on: 
Mardi, janvier 11, 2022
Transfer, Judge Advocate General's Corps, United States Department of Defense, Weapon, Natural language, JAG, CV, Computer vision, West Point Cemetery, Interest, Partnership, NATO, Lieber Institute for Brain Development, United States service academies, CEO, Department, Brennan Center for Justice, Defense Contract Management Agency, Organizational structure of the United States Department of Defense, Air force, Justice, STTR, Soldier, NLP, Artificial intelligence, Multimedia, AI, Air Operations Center, Brennan, War, Natural language processing, Risk management

However, Judge Advocates are not equipped to keep pace with modern combat.

Key Points: 
  • However, Judge Advocates are not equipped to keep pace with modern combat.
  • Legal experts include Professor Michael Schmitt, who is a distinguished scholar at both West Point and the U.S.
  • "We're proud to be the first small business to work with West Point in the STTR program," said James Julius, VISIMO founder and CEO.
  • VISIMO and West Point are currently seeking collaborators across the DoD to support the project's continued development in Phase II.

Boehringer Ingelheim and The Lieber Institute for Brain Development to Collaborate to Develop Centrally Acting COMT Inhibitors for Treatment of Neuropsychiatric Disorders

Retrieved on: 
Mardi, mars 16, 2021
Mental health, Health, Other Science, Research, Science, Pharmaceutical, Biotechnology, Medical specialties, Catechol-O-methyltransferase, Branches of biology, Clinical medicine, Lieber Institute for Brain Development, Parkinson's disease, Boehringer Ingelheim, Neuropsychiatry

Boehringer Ingelheim and the Lieber Institute for Brain Development (LIBD) today announced a joint research and licensing collaboration focused on the development of novel centrally acting COMT (catechol-O-methyltransferase) inhibitors for the potential treatment of cognitive deficits in a spectrum of neuropsychiatric disorders, including schizophrenia.

Key Points: 
  • Boehringer Ingelheim and the Lieber Institute for Brain Development (LIBD) today announced a joint research and licensing collaboration focused on the development of novel centrally acting COMT (catechol-O-methyltransferase) inhibitors for the potential treatment of cognitive deficits in a spectrum of neuropsychiatric disorders, including schizophrenia.
  • While peripherally acting COMT inhibitors are currently used as an adjunctive therapy in the treatment of neurological conditions, including Parkinsons disease, this new collaboration is investigating centrally acting COMT inhibitors in neuropsychiatric disorders.
  • Recent studies from the Lieber Institute suggest an important role of centrally acting COMT inhibitors in the potential symptomatic treatment of various neurological and neuropsychiatric disorders.
  • In partnering with the Lieber Institute, Boehringer Ingelheim has in-licensed preclinical pipeline candidates, representing a first-in-class approach for targets in neuropsychiatric disorders.

Brain & Behavior Research Foundation Receives $8 Million Bequest from Philanthropist and Mental Health Advocate Stephen Lieber

Retrieved on: 
Mardi, janvier 12, 2021
Brain & Behavior Research Foundation, Health, Mental health, Articles, Lieber Institute for Brain Development

New York, Jan. 12, 2021 (GLOBE NEWSWIRE) -- The Brain & Behavior Research Foundation today announced that is has received a bequest of $8 million from the noted philanthropist and mental health advocate Stephen Lieber.

Key Points: 
  • New York, Jan. 12, 2021 (GLOBE NEWSWIRE) -- The Brain & Behavior Research Foundation today announced that is has received a bequest of $8 million from the noted philanthropist and mental health advocate Stephen Lieber.
  • In fact, the vast majority of major scientific investigators studying the brain and human behavior have received Lieber philanthropic support.
  • With Connie and Steves support, the Brain & Behavior Research Foundation developed a uniquely warm, understanding and empathic approach to the patients, families and investigators of the broad mental health community.
  • The Brain & Behavior Research Foundation awards research grants to develop improved treatments, cures, and methods of prevention for mental illness.

African American Neuroscience Research Initiative Awarded Grant From Abell Foundation for Critical Program Support

Retrieved on: 
Vendredi, octobre 11, 2019
Lieber Institute for Brain Development, Neuroscience

BALTIMORE, Oct. 11, 2019 /PRNewswire/ -- The African American Neuroscience Research Initiative (AANRI) announced today the receipt of a $275,000 grant from the Abell Foundation, which will provide critical funds to support the development and growth of the collaboration between the African American Clergy Medical Research Initiative and the Lieber Institute for Brain Development.

Key Points: 
  • BALTIMORE, Oct. 11, 2019 /PRNewswire/ -- The African American Neuroscience Research Initiative (AANRI) announced today the receipt of a $275,000 grant from the Abell Foundation, which will provide critical funds to support the development and growth of the collaboration between the African American Clergy Medical Research Initiative and the Lieber Institute for Brain Development.
  • In neuroscience research studies of brain disorders, underrepresented minority groups, including African Americans, make up less than 5% of research cohorts.
  • For more information on the African American Neuroscience Research Initiative, visit aaneuroscience.com or contact Becky Oldham, Director of Communications at the Lieber Institute for Brain Development at [email protected] .
  • The African American Clergy Medical Research Initiative (AACMRI) is focused on ensuring that persons of African descent are equitably represented in medical research.